These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: An effective treatment of atypical hemolytic uremic syndrome with plasma exchange and eculizumab: A case report.
    Author: Sengul Samanci N, Ayer M, Ergen A, Ozturk S.
    Journal: Transfus Apher Sci; 2015 Jun; 52(3):314-6. PubMed ID: 25634788.
    Abstract:
    Atypical hemolytic uremic syndrome is a rare thrombotic microangiopathy caused by chronic defective regulation of the complement activation. This activation results in systemic endothelial damage leading to renal failure. Eculizumab, an anti-C5 antibody, is effective in limiting complement activation in patients with aHUS and has recently came out as a therapeutic option for aHUS. Here we present a case showing that first-line eculizumab treatment successfully prevents the induction of the terminal complement cascade and blocked the progression of thrombotic microangiopathy in aHUS.
    [Abstract] [Full Text] [Related] [New Search]